Cetirizine more potently exerts mast cell-stabilizing property than diphenhydramine
Author:
Affiliation:
1. Miyagi University, School of Nursing, Taiwa-cho, Miyagi, Japan.
Publisher
International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)
Subject
Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine
Link
https://www.jstage.jst.go.jp/article/ddt/16/5/16_2022.01067/_pdf
Reference33 articles.
1. 1. Church DS, Church MK. Pharmacology of antihistamines. World Allergy Organ J. 2011; 4:S22-27.
2. 2. del Cuvillo A, Mullol J, Bartra J, Davila I, Jauregui I, Montoro J, Sastre J, Valero AL. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol. 2006; 16 Suppl 1:3-12.
3. 3. Fein MN, Fischer DA, O'Keefe AW, Sussman GL. CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria. Allergy Asthma Clin Immunol. 2019; 15:61.
4. 4. Holmes JP, Peguero JA, Garland RC, North J, Young S, Brent LD, Joseph-Ridge N. Intravenous cetirizine vs intravenous diphenhydramine for the prevention of hypersensitivity infusion reactions: Results of an exploratory phase 2 study. J Infus Nurs. 2021; 44:315-322.
5. 5. Park JH, Godbold JH, Chung D, Sampson HA, Wang J. Comparison of cetirizine and diphenhydramine in the treatment of acute food-induced allergic reactions. J Allergy Clin Immunol. 2011; 128:1127-1128.
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Evolution, mechanism of action, and clinical applications of three generations of Antihistamines;Innovaciencia;2024-08-16
2. Mast Cell Activation Syndrome Update—A Dermatological Perspective;Journal of Personalized Medicine;2023-07-10
3. Brain Leukocytes as the Potential Therapeutic Target for Post-COVID-19 Brain Fog;Neurochemical Research;2023-03-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3